U.S. Markets open in 58 mins.

Antares Pharma, Inc. (ATRS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.53+0.08 (+3.27%)
At close: 4:00PM EDT
People also watch
ACRXCPRXGALEATHXAMRN
  • Waiting for the FDA
    Imagejjjjjjjjjjohn
  • We had an unbelievable run back up to 3's, but right now its just dead money until we start getting approvals, partnerships, ect. Epi will be here soon FINALLY should be approved in here in June at the latest. I believe we will be getting another turn around in June with EPI, I think with the fear of that shelf that was brought out, manipulation is being used against that fear. FDA needs to just get it done already this horse has been beaten to death already, get the paperwork signed and file it already with approval of epi so we can move on to the next. Long & Strong
  • Nam, here is a link:
    https://investorshub.advfn.com/boards/read_msg.aspx?message_id=51761776&txt2find=russell

    They took it up several month before and then down, similar to current pattern.
    I'm looking for short interest to have a large jump after the addition, but also hopping for a QST deal that will drive it higher.

    Antares Pharma, Inc. ATRS Post # 34
    Antares Pharma, Inc. ATRS Stock Message Board: [b]Antares Pharma Added to Russell 3000 Index[/b]
    investorshub.advfn.com
  • Consortium adds throughout retrace, Stockvadar-reports

    The story on Antares hasn't changed since Apple took over:
    they are rapidly moving to profitability and have a T- ROW
    to replenish the coffers... and Rescuject despite the fear-
    mongering for Epi-.

    But in addition to so many applications before the FDA,
    Antares is finally letting it be known that they have other
    projects in the works to continue to build long-term
    valuation. This, in our opinion, has mostly gone ignored
    except for a few savvy posts. Antares is apparently working
    on combination injections that Lokodaug has been wagging
    his tail about--good for him.

    As to why the stock retraced we see it as healthy for the
    long-term. WE've made our own sizeable purchases and
    are generally pleased to contemplate the long-term. TEVA
    knows how to bring a project to completion and WE remain
    confident that Epi news is coming any day.

    Irrespective WE hope to add another chunk to OUR
    portfolio should it again dip. If not, it's off for the ride
    which is going to be much much higher come 2018.

    It's interesting when your banker calls for advice, but
    apparently OUR savvy gains in Antares has drawn
    some attention. Finally, we're still a bit puzzled about
    what "M" is but are now wondering if Antares has plans
    to fast-forward one of its combination projects? Lokodaug
    might know as i-t eats the crumbs under Jack's table.

    -sv (STRONG BUY/HOLD)
  • Reason for the drop today. What the heck to these analysts know anyway.

    Barclays believes Mylan's base business appears on a more solid footing, on stabilizing generic pricing, performance potential of Meda, resolution of Agila warning letters and expectation that Epipen would stabilize.

    "We don't expect Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) to win AB-rating (ironically, the same questions on device interchangability that might block MYL's Advair ANDA will make approval of TEVA's product difficult," the firm said.
  • To the moon baby, to the moon
    Imageillmindmag
  • https://finance.yahoo.com/news/edited-transcript-atrs-earnings-conference-235558190.html

    "The next project, we are working on for Teva has a high public profile. As many of you know, Mylan's EpiPen product has been the subject of considerable public discussion over the past year and we will continue to work closely with Teva to help bring their generic version to the market. Teva has submitted all answers to all the questions in the complete response letter and is engaged in an ongoing dialog with the FDA.
    We continue to believe that there is a potential for a late 2017 or early 2018 launch of an AB rated generic and have indicated that a successful conclusion of this project remains a high priority for them. We continue to build and ship pre-launch quantities of Epi devices to Teva and are nearing the completion of the pre-launch quantity purchase order"

    GO ATRS!!!
    Long,

    Edited Transcript of ATRS earnings conference call or presentation 9-May-17 12:30pm GMT
    Q1 2017 Antares Pharma Inc Earnings Call
    finance.yahoo.com
  • how long does this bleeding last ....
  • I think Nam...errr...Dennis, forgot what happened last time ATRS (then AIS) was added to the Russell in 2010....
    OK Nam, time to do some homework...
    :o)
  • We could have a bottom here.
  • Barclay's said today it does not believe Teva will obtain AB rating on the Epipen. They claim interchangeabilility as noted with the Mylan Advair, is the issue. This may speak to the stock action today.
  • We need a catalyst "bridge" to cross the danger months of July thru August. I suspect that if NO CRL is sent by August 30, we should start a ramp upward toward October. However, with increasing market uncertainty and the usual ATRS uncertainty, which they seem to have attached to them like a caboose, the stock needs a shot of revenue expansion which an EPI approval would bring. Its EPI season right now.
  • playing games with stock, trying to walk it down. Looks like big money wants it lower to load up and scare out weak hands, watch your stops.
  • 2017 Reconstitution Russell

    May-ranking month

    May is “ranking” month when the largest US companies are lined up to form the preliminary Russell US reconstitution portfolios. In 2017, the rank day falls on Friday, May 12.



    June-transition month

    June is the month that the preliminary reconstitution portfolio is communicated to the marketplace. Beginning on June 9,preliminary lists are communicated to the marketplace and updates are provided on June 16 and 23. The newly reconstituted indexes take effect after the close on Friday, June 23.
  • Scott Gottlieb - Oct 24, 2016
    EpiPen Shows A Path To Solve The Bigger Drug Pricing Challenge
    https://www.forbes.com/sites/scottgottlieb/2016/10/24/epipen-drug-pricing-challenge/#1c0cade858a6

    March 10, 2017
    Trump Chooses Dr. Scott Gottlieb To Head Food And Drug Administration
    http://www.npr.org/sections/health-shots/2017/03/10/519703946/trump-to-nominate-dr-scott-gottlieb-to-head-food-and-drug-administration

    "I think Scott is absolutely qualified," lawyer John Taylor of Greenleaf Health tells STAT. "He has good professional credentials and personal integrity, and a track record that shows the ability to make difficult decisions."

    GO ATRS!!!
    Long,

    EpiPen Shows A Path To Solve The Bigger Drug Pricing Challenge
    Scrutiny of the high list price of the drug EpiPen, used for the emergency treatment of certain allergic reactions, exposed some of the craziness and inefficiency in how drugs are priced. But it also reveals problems with how certain medicines are de
    www.forbes.com
  • The old saying " If you build it they will come"

    ATRS: Milestones Continue to Align for Multiple 2018 Launches
    https://finance.yahoo.com/news/atrs-milestones-continue-align-multiple-210000905.html

    New Developments

    The trade name XYOSTED was selected for the QuickShot Testosterone product and publicly announced for the first time on the first quarter call.  The name was selected to resonate with both physicians and patients.  The first two letters “XY” represent the male chromosome and the target market for the product and the last four letters represent the acronym name of the Phase 3 clinical trial which was conducted in 2015 and 2016.  

    The goal for initial launch will be to initially hire district managers prior to the October PDUFA to identify sales candidates and develop messaging for the sales process.  Shortly after a favorable announcement from the FDA on XYOSTED, hiring of the sales force will take place, targeting 60 reps that will target primary care physicians, urologists and endocrinologists. 

    Antares is currently consulting with third party payors and payor advisory boards to refine pricing and formulary positioning.  The company has also conducted advisory meetings and focus group seminars with key opinion leaders in urology and endocrinology to understand the marketplace and the needs of the medical community and patients.  Quick shot testosterone can potentially take a dominant position in the market for testosterone deficiency and given its particular benefits, and may capture share from the injectable and topical administration competitors.  

    Other new developments include progress in Europe with Teva’s generic Forteo (teriparatide) pen-injector.  At the end of last year, teriparatide was successfully registered under the decentralized procedure and was filed in 17 European countries, which is broader than the five countries indicated in Teva’s previous commentary.  

    GO ATRS!!!
    Long,

  • Sell in May and go away would have been spot on for ATRS this month. Been a ride down for sure!
  • Good news is I just snagged a bunch more shares at 2.60 :) End of the year will be glorious our HOT SP will keep warm through the winter! 2018 Even more!! Long & Strong
  • Never post here i have had shares for along time tho. Wondering thoughts on price action today ...Semms like when i check http://www.nasdaq.com/symbol/atrs/time-sales there are lots and lots of buys for 100-200 shares ...are they trying to load and keep price pinned ?

    Time and Sales - Intraday Stock Last Price History for Antares Pharma, Inc. (ATRS)
    NASDAQ Last Sale (NLS) Intraday Stock History Report: Time and sales data for Antares Pharma, Inc. (ATRS)
    www.nasdaq.com
  • Wish we keep politics of this board but help each other to make money. Chart wise- if SP does not hold her next support at $2.40